In Hae Park

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology · 2017 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +16

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer

So‐Youn Jung, Hyun Yul Kim, Byung‐Ho Nam et al. · Breast Cancer Research and Treatment · 2010 · 217 citations

Medicine, Cancer Biology, Oncology +12

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: ALTERNATIVE

Stephen Johnston, Roberto Hegg, Seock‐Ah Im et al. · Journal of Clinical Oncology · 2017 · 166 citations · Full text

Medicine, Oncology, Pharmacology +17

Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial

Yeon Hee Park, Tae‐Yong Kim, Gun Min Kim et al. · The Lancet Oncology · 2019 · 130 citations

Medicine, Oncology, Pharmacology +16